Onco Wiki / Maladie

Ovarian carcinoma (high-grade serous predominant)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-OVARIAN
TypeMaladie
Alias
Cancer épithélial des ovairesCarcinome ovarienCancer de l'ovaire tubo (y compris le tube de Fallope + péritonéal primaire)Карцинома яєчників (переважно high-grade серозна)
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8441/3
icd_o_3_topography["C56", "C57.0", "C48.1"]
icd_10C56
who_classificationWHO Female Genital Tumours 5th ed (2020): High-grade serous carcinoma of tubo-ovarian / peritoneal origin

Capacités

Notes

Scaffolded for batch #2: focus on advanced-stage (FIGO III-IV) HGSC 1L systemic + maintenance. 4 RFs (debulking-status MDT-trigger, HRD-actionability, frailty/age, perioperative VTE risk). Regimens: carbo+pacli ± bev backbone, olaparib maintenance HRD+, niraparib all-comer maintenance, bev maintenance per PAOLA-1. Out-of-scope this commit: rare histologies (clear-cell, endometrioid, mucinous, low-grade serous have distinct paradigms); recurrent platinum-sensitive vs platinum-resistant 2L+ algorithms; borderline tumors. HRD testing (BIO-HRD-STATUS) is the central biomarker — defines PARPi-maintenance benefit. BRCA1/2 germline + somatic via reflex testing.

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Chapitres du manuel

Indication

Procédures

Questionnaires

Signal d’alerte

Sources